Frailty Models for Familial Risk With Application to Breast Cancer
暂无分享,去创建一个
[1] S. Cummings,et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Hajime Uno,et al. Calibrating parametric subject-specific risk estimation. , 2010, Biometrika.
[3] Youngjo Lee,et al. Hierarchical likelihood approach for frailty models , 2001 .
[4] Dorota M. Dabrowska,et al. Uniform Consistency of the Kernel Conditional Kaplan-Meier Estimate , 1989 .
[5] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[6] D.,et al. Regression Models and Life-Tables , 2022 .
[7] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[8] Leif E. Peterson,et al. Validity of Models for Predicting BRCA1 and BRCA2 Mutations , 2007, Annals of Internal Medicine.
[9] G. Mills,et al. Assessing BRCA carrier probabilities in extended families. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Buell. Changing incidence of breast cancer in Japanese-American women. , 1973, Journal of the National Cancer Institute.
[11] S Wacholder,et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. , 1999, American journal of human genetics.
[12] J. Cuzick. Event-based analysis times for randomised clinical trials , 2001 .
[13] H. Nevanlinna,et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.
[14] Alfred A. Boyd,et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.
[15] Malka Gorfine,et al. Prospective survival analysis with a general semiparametric shared frailty model: A pseudo full likelihood approach , 2005 .
[16] Nilanjan Chatterjee,et al. Case–Control and Case‐Only Designs with Genotype and Family History Data: Estimating Relative Risk, Residual Familial Aggregation, and Cumulative Risk , 2006, Biometrics.
[17] D. Berry,et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.
[18] Leif E. Peterson,et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Malka Gorfine,et al. Missing genetic information in case-control family data with general semi-parametric shared frailty model , 2011, Lifetime data analysis.
[20] C. Begg,et al. Variation of breast cancer risk among BRCA1/2 carriers. , 2008, JAMA.
[21] E. Murphy,et al. The Application of Bayesian Methods in Genetic Counselling , 1969 .
[22] Malka Gorfine,et al. Calibrated predictions for multivariate competing risks models , 2014, Lifetime data analysis.
[23] D. Berry,et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. , 1998, Journal of the National Cancer Institute.
[24] Hormuzd A Katki,et al. Effect of Misreported Family History on Mendelian Mutation Prediction Models , 2006, Biometrics.
[25] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[26] Donglin Zeng,et al. Maximum likelihood estimation in semiparametric regression models with censored data , 2007, Statistica Sinica.
[27] Malka Gorfine,et al. CASE-CONTROL SURVIVAL ANALYSIS WITH A GENERAL SEMIPARAMETRIC SHARED FRAILTY MODEL - A PSEUDO FULL LIKELIHOOD APPROACH. , 2009, Annals of statistics.
[28] H A Risch,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.
[29] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[30] N E Day,et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.
[31] Donald A. Berry,et al. Modeling Risk of Breast Cancer and Decisions about Genetic Testing , 1999 .
[32] L. Hsu,et al. A Frailty‐Model‐Based Approach to Estimating the Age‐Dependent Penetrance Function of Candidate Genes Using Population‐Based Case‐Control Study Designs: An Application to Data on the BRCA1 Gene , 2009, Biometrics.
[33] M. Gorfine,et al. Semiparametric Estimation of Marginal Hazard Function from Case–Control Family Studies , 2004, Biometrics.
[34] Daniel Zelterman,et al. Modeling Survival Data: Extending the Cox Model , 2002, Technometrics.
[35] Karl W Broman,et al. BayesMendel: an R Environment for Mendelian Risk Prediction , 2004, Statistical applications in genetics and molecular biology.
[36] James R. Kenyon,et al. Analysis of Multivariate Survival Data , 2002, Technometrics.
[37] Paul Janssen,et al. Frailty Model , 2007, International Encyclopedia of Statistical Science.
[38] N. Chatterjee,et al. Analysis of Survival Data from Case–Control Family Studies , 2002, Biometrics.
[39] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.